酪氨酸激酶抑制剂在高危肾细胞癌辅助治疗中的优势：一项荟萃分析。
The merit of tyrosine kinase inhibitors in the adjuvant setting of high-risk renal cell carcinoma: a meta-analysis.
机构信息
Laboratory of Medical Genetics, Faculty of Medicine, Campus of Innovation & Sport, University of Saint-Joseph, Damascus street, PO Box 17-5208 Mar Mikhael, Beirut, Lebanon.
Hematology-Oncology Department, Hotel-Dieu de France Hospital, University of Saint-Joseph, Beirut, Lebanon.
出版信息
Future Oncol. 2018 Apr;14(9):829-835. doi: 10.2217/fon-2017-0333. Epub 2018 Mar 28.
AIM
As no meta-analyses have evaluated tyrosine kinase inhibitors in the adjuvant setting of high-risk renal cell carcinoma (RCC), the aim was to evaluate the benefit of sunitinib and pazopanib in the adjuvant setting.
METHODS
This meta-analysis included all Phase III randomized controlled trials evaluating adjuvant sunitinib and pazopanib in high-risk RCC. Primary outcome was the comparison of disease-free survival (DFS) between tyrosine kinase inhibitors and placebo.
RESULTS
There was a tendency for significant overall effect of both sunitinib and pazopanib on DFS (hazard ratio: 0.85; 95% confidence interval: 0.72-1.01; p = 0.06). There was no significant difference between the effect of sunitinib and pazopanib on DFS (p = 0.51; I = 0%).
CONCLUSION
Pazopanib and sunitinib could prolong DFS in the adjuvant treatment of high-risk RCC and seem equally effective in this setting.
目的
由于目前尚无荟萃分析评估酪氨酸激酶抑制剂在高危肾细胞癌（RCC）辅助治疗中的作用，本研究旨在评估舒尼替尼和帕唑帕尼在辅助治疗中的获益。
方法
本荟萃分析纳入了所有评估辅助舒尼替尼和帕唑帕尼治疗高危 RCC 的 III 期随机对照试验。主要结局是比较酪氨酸激酶抑制剂与安慰剂在无病生存期（DFS）方面的差异。
结果
舒尼替尼和帕唑帕尼在 DFS 方面均有显著的总体获益趋势（风险比：0.85；95%置信区间：0.72-1.01；p = 0.06）。舒尼替尼和帕唑帕尼在 DFS 方面的疗效无显著差异（p = 0.51；I² = 0%）。
结论
帕唑帕尼和舒尼替尼可延长高危 RCC 患者的 DFS，并在该治疗环境中似乎同样有效。
Zotero 插件